Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).
IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2). D'Angelo, S. P., Noujaim, J., Thistlethwaite, F., Razak, A., Stacchiotti, S., Chow, W., Haanen, J. G., Chalmers, A., Robinson, S., Van Tine, B., Ganjoo, K. N., Johnson, M. L., Chiou, V. L., Faitg, T. H., Woessner, M., Pearce, L., Shalabi, A., Blay, J., Demetri, G. LIPPINCOTT WILLIAMS & WILKINS. 2021View details for DOI 10.1200/JCO.2021.39.15_suppl.TPS11582
View details for Web of Science ID 000708120306173